SIGY — Sigyn Therapeutics Balance Sheet
0.000.00%
- $5.67m
- $7.72m
Annual balance sheet for Sigyn Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.084 | 0.341 | 0.008 | 0.012 | 0.012 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 0 | — | — | — |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.67 | 0.393 | 0.07 | 0.118 | 0.021 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.002 | 0.291 | 0.24 | 0.183 | 0.122 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 0.694 | 0.71 | 0.333 | 0.322 | 0.214 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.595 | 0.734 | 2.05 | 3.61 | 4.61 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.595 | 0.975 | 2.24 | 3.73 | 4.67 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.099 | -0.265 | -1.9 | -3.41 | -4.46 |
Total Liabilities & Shareholders' Equity | 0.694 | 0.71 | 0.333 | 0.322 | 0.214 |
Total Common Shares Outstanding |